Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3498784 | 0.83 | G6PD (0.46) | G6PDCASP7CASP6THRBMMP2 | |
| SCHEMBL9845939 | 0.82 | G6PD (0.34) | G6PDCASP7CASP6MMP2ALDH1A1 | |
| SCHEMBL519802 | 0.79 | ENPP2 (0.41) | ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA | |
| SCHEMBL29469063 | 0.79 | ENPP2 (0.41) | ALDH1A1KDM4ESMN1; SMN2KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL1451940 | 0.78 | ALDH1A1 (0.53) | CASP7ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL28018486 | 0.78 | AKT1 (0.37) | G6PDCASP7CASP6THRBMMP2 | |
| SCHEMBL3784961 | 0.78 | THRB (0.45) | THRBALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL505381 | 0.77 | MMP2 (0.47) | G6PDCASP7CASP6THRBMMP2 | |
| SCHEMBL1066809 | 0.76 | CES2 (0.41) | THRBALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL3586373 | 0.75 | CA12 (0.38) | G6PDCASP7CASP6THRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517896-B2 | Aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7087622-B2 | Pyridone compounds as inhibitors of bacterial type III protein secreation systems | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-08 | — | — | US | disclosed |
| US-20060094769-A1 | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| WO-2005110988-A1 | PYRIDONE COMPOUNDS AS INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256137-A1 | Pyridone compounds as inhibitors of bacterial type III protien secreation systems | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094769-A1 | Novel aminodicarboxylic acid derivatives having pharmaceutical properties | DDC, AADAT, PTGIS | G6PD 1558/4885CASP7 2087/4885CASP6 457/4885 |
| US-20050256137-A1 | Pyridone compounds as inhibitors of bacterial type III protien secreation systems | PROC, PSMB3, PANK3 | G6PD 1494/4885CASP7 1652/4885CASP6 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.